scholarly journals Clinicopathological and Prognostic Significance of Maspin Expression in Resected Non-Small Cell Lung Cancer: A Meta-Analysis

2020 ◽  
Author(s):  
Yan Wang ◽  
Yi Wang ◽  
Yingxian Dong ◽  
Jialong Li ◽  
Guowei Che
Keyword(s):  
Lung Cancer ◽  
Prognostic Significance ◽  
Clinicopathological Characteristics ◽  
Small Cell ◽  
Small Cell Lung ◽  
P53 Expression ◽  
Node Metastasis ◽  
Resected Nsclc ◽  
Maspin Expression ◽  
Nsclc Patients

Abstract Objective To explore the association of maspin expression with clinical pathological parameters and prognosis in non-small cell lung cancer (NSCLC) who received the surgical therapy.Methods The EMBASE, Web of Science and PubMed were searched to identify eligible studies to 3 December, 2019. The correlation of maspin expression with clinicopathological characteristics and survival of resected NSCLC patients was assessed by the combined relative risk (RR) and hazard ratio (HR) with corresponding 95% confidence interval (CI), respectively. All statistical analyses were performed via the Stata 12.0 software.Results A total of 12 articles involving 1771 patients were included. The results manifested that maspin was more prevalent in lung squamous cell carcinoma (SCC) (RR=0.36, 95% CI: 0.22-0.60, P＜0.001) and significantly associated with P53 expression (RR=1.50, 95% CI: 1.00-2.24, P=0.048), while no significant correlation of maspin with other clinicopathological parameters such as the gender, age, tumor size, lymph node metastasis, tumor node metastasis (TNM) stage or differentiation status was observed. As for the prognosis representing as overall survival (OS), disease-free survival (DFS) and cancer-specific survival (CSS), only significant association between maspin and CSS (HR=1.58, 95% CI: 1.16-2.15, P=0.003) was revealed. However, the subgroup analysis for OS based on the histology demonstrated that maspin expression was an unfavourable and favourable prognostic indicator in lung adenocarcinoma (HR=3.36, 95% CI: 1.44-7.87, P=0.005) and SCC (HR=0.44, 95% CI: 0.27-0.71, P=0.001), respectively.Conclusion Maspin expression was correlated with histology type and P53 expression, but no certain association of maspin with other clinicopathological characteristics or prognosis was observed in resected NSCLC. More well-designed prospective researches with big samples are still needed to further assess the clinicopathological and prognostic significance of maspin in NSCLC patients undergoing surgical resection.

scholarly journals Clinicopathological and prognostic significance of maspin expression in resected non-small cell lung cancer: a meta-analysis

2020 ◽  
Author(s):  
Yan Wang ◽  
Yingxian Dong ◽  
Yanwen Wang ◽  
Jialong Li ◽  
Guowei Che
Keyword(s):  
Lung Cancer ◽  
Prognostic Significance ◽  
Clinicopathological Characteristics ◽  
Small Cell ◽  
Small Cell Lung ◽  
P53 Expression ◽  
Node Metastasis ◽  
Resected Nsclc ◽  
Maspin Expression ◽  
Nsclc Patients

Abstract Objective To explore the association of maspin expression with clinical pathological parameters and prognosis in non-small cell lung cancer (NSCLC) who received the surgical therapy. Methods The EMBASE, Web of Science and PubMed were searched to identify eligible studies to 3 June, 2019. The correlation of maspin expression with clinicopathological characteristics and survival of resected NSCLC patients was assessed by the combined relative risk (RR) and hazard ratio (HR) with corresponding 95% confidence interval (CI), respectively. All statistical analyses were performed via the Stata 12.0 software. Results A total of 12 articles involving 1771 patients were included. The results manifested that maspin was more prevalent in lung squamous cell carcinoma (SCC) (RR=0.36, 95% CI: 0.22-0.60, P <0.001) and significantly associated with P53 expression (RR=1.50, 95% CI: 1.00-2.24, P =0.048), while no significant correlation of maspin with other clinicopathological parameters such as the gender, age, tumor size, lymph node metastasis, tumor node metastasis (TNM) stage or differentiation status was observed. As for the prognosis representing as overall survival (OS), disease-free survival (DFS) and cancer-specific survival (CSS), only significant association between maspin and CSS (HR=1.58, 95% CI: 1.16-2.15, P =0.003) was revealed. However, the subgroup analysis for OS based on the histology demonstrated that maspin expression was an unfavourable and favourable prognostic indicator in lung adenocarcinoma (HR=3.36, 95% CI: 1.44-7.87, P =0.005) and SCC (HR=0.44, 95% CI: 0.27-0.71, P =0.001), respectively. Conclusion Maspin expression was correlated with histology type and P53 expression, but no certain association of maspin with other clinicopathological characteristics or prognosis was observed in resected NSCLC. More well-designed prospective researches with big samples are still needed to further assess the clinicopathological and prognostic significance of maspin in NSCLC patients undergoing surgical resection.

scholarly journals Forkhead box 1 expression is upregulatedin non-small cell lung cancer and correlateswith pathological parameters

2016 ◽  
Vol 11 (1) ◽  
pp. 220-224
Author(s):  
Chongwei Wang ◽  
Chongbang Wang ◽  
Shufang Duan
Keyword(s):  
Gene Expression ◽  
Lung Cancer ◽  
Overall Survival ◽  
Lymph Node ◽  
Lymph Node Metastasis ◽  
Small Cell ◽  
Small Cell Lung ◽  
Node Metastasis ◽  
Forkhead Box ◽  
Nsclc Patients

AbstractObjectives: As the member of the Fox family of transcription factors, Forkhead box M1 (FoxM1) is known to be critical in pathogenesis and development of many solid tumors. However, the clinical value and expression pattern in non-small cell lung cancer (NSCLC) is still poorly understood. Methods: In this study, real-time PCR was mainly applied to examine the gene expression levels of FoxM1 in 120 pairs of clinical NSCLC tissues, which were classified into different groups according to smoking status, lymph node metastasis, and tumor grade. By utilizing the online Kaplan-Meier plotter, overall survival analysis was performed to study the correlation between FoxM1 expression and prognosis of lung cancer (LC) patients. Afterwards, the correlation of FoxM1 gene expression and the clinical pathological parameters was examined by κ2 test in these 120 NSCLC patients. Results: FoxM1 was found to be aberrantly upregulated in NSCLC patients, and its overexpression was correlated to groups designated as smokers, cases of positive lymph node metastasis and cases of advanced tumor grades. Online survival analysis showed that high expression of FoxM1 predicted shorter overall survival of NSCLC patients. Additionally, FoxM1 upregulation was statistically correlated with positive smoking history, lymph node metastasis and higher tumor grades. Conclusion: FoxM1 is overexpressed in cancerous tissues and is associated with the poor prognosis of NSCLC patients. Our results provide insights into the utility of FoxM1 as an important biomarker and prognostic factor for NSCLC.

A Meta Analysis on Prognostic Value of Patients with Non-Small Cell Lung Cancer

2018 ◽  
Vol 8 (9) ◽  
pp. 1875-1880
Author(s):  
Jiang Rui ◽  
Li Yingping ◽  
Lijun Gu ◽  
Zhiyan Wang ◽  
Jing Zuo ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Meta Analysis ◽  
Prognostic Significance ◽  
Small Cell ◽  
Significant Heterogeneity ◽  
Small Cell Lung ◽  
Survival Prognosis ◽  
Nsclc Patients

Nuclear factor kappa B (NF-κB), a key nuclear transcription factor, is associated with prognosis in a variety of human cancers. However, the clinical value of NF-κB in non-small cell lung cancer (NSCLC) is still controversial. Therefore, the aim of this meta-analysis was to obtain an accurate evaluation of the relationship between NF-κB expression and survival prognosis of NSCLC patients based on published articles. PubMed, EMBASE and Web of Science databases were systematically searched for potential articles. A total of 1159 patients from 7 eligible studies comparing prognostic significance of NF-κB expression levels in NSCLC were included in our meta-analysis. I2 statistic and P value were performed to evaluate heterogeneity using Review Manager version 5.3. The results of analysis were presented as hazard ratio (HR) or odds ratios with 95% confidence interval (95% CI). Subgroup analysis based on ethnicity of NSCLC patients was conducted to illustrate the potential discrepancy. Significant heterogeneity was considered at I2 > 50% and P < 0.05, and random-effects model was used. The combined results indicated that higher NF-κB expression was associated with shorter overall survival of NSCLC patients (HR = 2.78, 95% CI = 1.51–5.12, P = 0.001). Moreover, NF-κB expression was closely associated with tumor stage (HR = 0.32, 95% CI = 0.18–0.57, P < 0.0001) and lymph node metastasis (HR = 0.56, 95% CI = 0.38–0.83, P = 0.004). We conclude that NF-κB expression may be a potential unfavorable prognostic marker for NSCLC patients.

Increased incidence of brain metastases in ERCC1-negative NSCLC patients treated with adjuvant cisplatin-based chemotherapy

2007 ◽  
Vol 25 (18_suppl) ◽  
pp. 7581-7581
Author(s):  
B. Besse ◽  
C. Massard ◽  
V. Haddad ◽  
F. André ◽  
A. Dunant ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Adjuvant Chemotherapy ◽  
Brain Metastases ◽  
Small Cell ◽  
Clinical Parameters ◽  
Small Cell Lung ◽  
Resected Nsclc ◽  
Increased Risk ◽  
Metastatic Sites ◽  
Nsclc Patients

7581 Background: We have recently demonstrated that ERCC1 is a predictor of the benefit of cisplatin-based adjuvant chemotherapy in resected non-small cell lung cancer (NSCLC). Non-squamous carcinomas have an increased risk of brain metastases (BM). Since brain is considered as a sanctuary site for chemotherapy, we hypothesised that there was an increased incidence of BM in ERCC1- negative non-squamous NSCLC patients treated with adjuvant cisplatin-based chemotherapy. Methods: Incidence of BM and histo- clinical parameters were analyzed in a population of 783 patients enrolled in the IALT trial. A subgroup analysis was performed in ERCC1 negative non-squamous NSCLC patients. Results: One hundred and one patients out of 783 (13%) developed BM alone or in association with other metastatic sites. In multivariate analysis, the clinical parameters associated with the occurrence of BM were nodal status (p=0.02), histological type (p=0.001) and pleural invasion (p=0.02). There is no effect of chemotherapy on BM (HR 1.38 [0.91–2.07], p=0.13). In patients with non-squamous histology (n=335) adjuvant chemotherapy was associated with an increased risk of BM (HR=2.10, [1.01–4.32], p=0.04) for ERCC1-negative tumours whereas there was no evidence of an effect on brain metastasis for ERCC1-positive tumours (HR=1.07 [0.38–2.99] p=0.90). These 2 effects are nevertheless not different (p for interaction=0.30) possibly by lack of power in this subsample. Conclusions: This study would suggest that cisplatin-based adjuvant chemotherapy is associated with an increased risk of BM in resected NSCLC patients with chemosensitive tumors. This data, if confirmed, could provide a rationale to evaluate prophylactic strategies in this subset of patients. No significant financial relationships to disclose.

scholarly journals Expression and Diagnostic Efficacy of miR-126-5p and miR-34c-3p in Serum Extracellular Vesicles of Non-Small Cell Lung Cancer Patients

2021 ◽  
Author(s):  
Jie Zhao ◽  
Wenlu Hang ◽  
Qian Wang ◽  
Yonghong Xu
Keyword(s):  
Lung Cancer ◽  
Lymph Node ◽  
Lymph Node Metastasis ◽  
Small Cell Lung Cancer ◽  
Poor Prognosis ◽  
Clinical Stage ◽  
Small Cell ◽  
Small Cell Lung ◽  
Node Metastasis ◽  
Nsclc Patients

Abstract Background: Non-small cell lung cancer (NSCLC) is a disease with quite grave prognosis. This study explored the diagnostic efficiency of miR-126-5p and miR-34c-3p in serum extracellular vesicles (EVs) in NSCLC patients.Methods: Serum EVs were extracted from NSCLC patients and healthy people and verified. The expression of miR-126-5p and miR-34c-3p in serum EVs were tested. Correlation of miR-126-5p and miR-34c-3p expression and diagnosis, prognosis and pathological characteristics (age, gender, tumor size, clinical stage, and lymph node metastasis) of NSCLC patients was analyzed. The downstream targets of miR-126-5p and miR-34c-3p were predicted and their roles in diagnosis and prognosis of NSCLC patients were evaluated.Results: miR-126-5p and miR-34c-3p were poorly expressed in serum EVs of NSCLC patients and their low expressions were associated with clinical stage, lymph node metastasis and prognosis of NSCLC patients and could be used as biomarkers for diagnosis. As the common target genes of miR-126-5p and miR-34c-3p, LYPLA1 and CDK6 were highly expressed in serum EVs and were associated with poor prognosis in NSCLC patients.Conclusion: Lowly expressed miR-126-5p and miR-34c-3p in serum EVs of NSCLC patients can serve as biomarkers for diagnosis and are linked with prognosis. As common targets of miR-126-5p and miR-34c-3p, LYPLA1 and CDK6 are also associated with poor prognosis in NSCLC patients.

scholarly journals The Impact of Programmed Death-Ligand 1 Expression on the Prognosis of Early Stage Resected Non-Small Cell Lung Cancer: A Meta-Analysis of Literatures

2021 ◽  
Vol 11 ◽  
Author(s):  
Tao Shi ◽  
Shuai Zhu ◽  
Hengjuan Guo ◽  
Xiongfei Li ◽  
Shikang Zhao ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Early Stage ◽  
Meta Analysis ◽  
Small Cell ◽  
Cochrane Library ◽  
Small Cell Lung ◽  
Resected Nsclc ◽  
Nsclc Patients

IntroductionPrevious studies have demonstrated that programmed cell death-ligand 1 (PD-L1) serves as biomarker for poor prognosis and survival in advanced-stage non-small cell lung cancer (NSCLC) patients. However, the merit of PD-L1 expression to predict the prognosis of early stage NSCLC patients who underwent complete resection remains controversial. In the present study, we performed a meta-analysis to investigate the relationship between PD-L1 expression and prognosis in patients with early stage resected NSCLC.MethodsElectronic databases, including PubMed, EMBASE, and the Cochrane Library, were searched until July 23 2020 for studies evaluating the expression of PD-L1 and the prognosis of resected NSCLCs. Hazard ratios (HRs) with 95% confidence intervals (CIs) of overall survival (OS) and disease-free survival (DFS) were pooled and analyzed. Heterogeneity and publication bias analyses were also assessed.ResultsA total of 15 studies involving 3,790 patients were considered in the present meta-analysis. The pooled HR indicated that PD-L1 expression related to a much shorter DFS (HR = 1.56, 95% CI: 1.18–2.05, p &lt; 0.01), as well a significantly worse OS (HR = 1.68, 95% CI: 1.29–2.18, p &lt; 0.01). Furthermore, our analysis indicated that PD-L1 expression was significantly associated with gender (male vs. female: OR = 1.27, 95% CI:1.01–1.59, p = 0.038), histology (ADC vs. SCC: OR = 0.54, 95% CI:0.38–0.77, p = 0.001), TNM stage (I vs. II–III: OR = 0.45, 95% CI:0.34–0.60, p = 0.000), smoking status (Yes vs No: OR = 1.43, 95% CI:1.14–1.80, p = 0.002) and lymph node metastasis (N+ vs N−: OR = 1.97, 95% CI:1.26–3.08, p = 0.003).ConclusionsThe results of this meta-analysis suggest that PD-L1 expression predicts an unfavorable prognosis in early stage resected NSCLCs. The role of personalized anti-PD-L1/PD-1 immunotherapy in the adjuvant settings of resected NSCLC warrants further investigation.

Prognostic significance of aneuploidy in non-small cell lung cancer (NSCLC) patients (pts)

2004 ◽  
Vol 22 (14_suppl) ◽  
pp. 7319-7319
Author(s):  
R. Dziadziuszko ◽  
E. Wegrzynowicz ◽  
I. Kardas ◽  
J. Limon ◽  
J. Jassem
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Prognostic Significance ◽  
Small Cell ◽  
Small Cell Lung ◽  
Nsclc Patients

Retinoblastoma mutation to predict poor outcomes in non-small cell lung cancer (NSCLC).

2017 ◽  
Vol 35 (15_suppl) ◽  
pp. 9060-9060
Author(s):  
Priyanka Bhateja ◽  
Gary Wildey ◽  
Pingfu Fu ◽  
Mary Beth Lipka ◽  
Fatemeh Ardeshir-Larijani ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Prognostic Significance ◽  
Small Cell ◽  
Smoking History ◽  
Secondary Outcome ◽  
P Value ◽  
Small Cell Lung ◽  
Nsclc Patients

9060 Background: Genomic profiling of tumor DNA has revealed the diversity in NSCLC. The retinoblastoma gene ( RB1) encodes for RB pocket protein that plays an important role in cell cycle progression by interacting with various transcriptional factors. Here we determine the frequency and prognostic significance of RB1mutation in NSCLC and compare it to that in small cell lung cancer (SCLC). Methods: This IRB-approved retrospective review on NSCLC patients included Stage III and IV patients with genomic and clinical data. Primary outcome was median overall survival (OS) and secondary outcome was progression-free survival (PFS). OS and PFS were calculated by the Kaplan-Meier method and compared between mutant and wild-type (wt) RB1using the Log-Rank test. The effect of RB1mutation status on OS and PFS was further evaluated using the multivariable Cox model, controlling the effects of age, sex, stage, smoking history and chemotherapy. All tests are two-sided and p-values ≤ 0.05 were considered statistically significant. Results: We identified RB1 mutation in 8.2% of NSCLC patients (16 of 195 patients). With a median follow-up of 15.1 months, the median OS for wt RB1was 28.3 months and for mutant RB1 was 8.3 months (HR = 2.59, p-value = 0.002). The median PFS for wt RB1 was 21.8 months vs 6.4 months for mutant RB1 (HR = 2.85, p-value = 0.0002). RB1 mutation was associated with worse OS ( p= 0.017, HR = 2.17) and PFS ( p= 0.005, HR = 2.37) in multivariate analyses after adjusting for traditional risk factors like, age, sex, stage, smoking history and chemotherapy. Interestingly, a previously described benign deletion (A16-A18) in RB1 protein was identified in 5 of the 16 RB1 mutant patients and was associated with far worse outcomes compared to other RB1 mutations. In contrast to NSCLC, RB1 mutation was identified in 75% of 64 SCLC patients. Furthermore, wt RB1 was associated with significantly shorter OS ( p= 0.002), PFS ( p= 0.004) and chemotherapy refractoriness ( p= 0.033) in SCLC. Conclusions: RB1 mutation is present in a minority of patients with advanced NSCLC and is associated with poor prognosis. In contrast, RB1 mutation is present in the majority of SCLC patients and is associated with a favorable prognosis.

A nomogram for predicting overall survival in resected non-small cell lung cancer with chemotherapy.

2020 ◽  
Vol 38 (15_suppl) ◽  
pp. e21064-e21064
Author(s):  
Yuan Zeng ◽  
Wenhua Liang ◽  
Jianxing He
Keyword(s):  
Lung Cancer ◽  
Overall Survival ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Seer Database ◽  
Small Cell Lung ◽  
Lymph Node Count ◽  
Resected Nsclc ◽  
Nsclc Patients

e21064 Background: Chemotherapy is very common for resected Non-Small-Cell Lung Cancer (NSCLC) patients. However, models for predicting the survival outcomes of resected NSCLC patients with chemotherapy are scarce. The aim of this study was to develop a clinical nomogram for predicting overall survival in these patients. Methods: A total of 16661 resected NSCLC with chemotherapy were cases extracted from the Surveillance, Epidemiology, and End Results (SEER) database. We identified and integrated the prognostic factors to build a nomogram.The model was subjected to bootstrap internal validation with the SEER database and external validations with 1108 patients from China. The predictive accuracy and discriminative ability were illustrated by calibration, concordance index (C-index) and risk group stratification. Results: On multivariate analysis independent factors for OS were age, sex, examined lymph node count, extent of surgery, N stage, T stage and grade which were then integrated into the nomogram. The calibration curves for probability of 1-, 3-, and 5-year OS showed excellent agreement between nomogram prediction and actual observation. The C-index of the nomogram was higher than that of AJCC 8th edition system for predicting OS (training cohort, 0.61 vs. 0.58; P < 0.01; validation cohort, 0.66 vs. 0.63, P = 0.56). The stratification into different risk groups allowed significant distinction between survival curves. Conclusions: We established a nomogram that can provide individual prediction of OS for resected NSCLC patients with chemotherapy. This practical prognostic model may help clinicians for treatment planning and to guide future studies.

Sign in / Sign up

Export Citation Format

Share Document